<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Children with <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> have an increased risk of developing a <z:mp ids='MP_0000948'>nonconvulsive</z:mp> <z:hpo ids='HP_0002133'>status epilepticus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the urgency to treat <z:mp ids='MP_0000948'>nonconvulsive</z:mp> <z:hpo ids='HP_0002133'>status epilepticus</z:hpo> depends on the underlying illness, most clinicians and authors agree that treatment should be focused to rapidly terminate this condition </plain></SENT>
<SENT sid="2" pm="."><plain>Until now, the use of levetiracetam to treat <z:mp ids='MP_0000948'>nonconvulsive</z:mp> <z:hpo ids='HP_0002133'>status epilepticus</z:hpo> in children is based only on some case reports </plain></SENT>
<SENT sid="3" pm="."><plain>Our case further supports this treatment regime for a subgroup of children with a special risk of <z:mp ids='MP_0000948'>nonconvulsive</z:mp> <z:hpo ids='HP_0002133'>status epilepticus</z:hpo> and <z:hpo ids='HP_0001263'>developmental delay</z:hpo> </plain></SENT>
</text></document>